David Apelian - Jan 31, 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role
Interim CEO, Director
Signature
/s/ David Apelian
Stock symbol
EIGR
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 08:12 PM
Previous filing
Aug 18, 2022
Next filing
Jul 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +170K $0.00 170K Jan 31, 2023 Common Stock 170K $1.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 113,900 shares upon the earlier to occur of (i) on the six-month anniversary of December 14, 2022 or (ii) the Company's appointment of a full-time non-interim Chief Executive Officer, and as to the remaining 56,100 shares in six equal monthly installments measured from December 14, 2022, subject to the Reporting Person's continuous service as of each such date.